(CercleFinance.com) – GSK on Wednesday reported higher earnings per share and revenue in the second quarter, in which it continued to benefit from strong demand for its shingles vaccine , Shingrix.
The first British laboratory announced this morning that its adjusted earnings per share (EPS) stood at 34.7 pence over the past quarter, an increase of 6% on a like-for-like basis.
Its turnover reached 6.9 billion pounds sterling, an increase of 13% excluding currency effects, thanks to the double-digit growth recorded by Shingrix, whose sales set new records.
After these performances which it considers ‘solid’, the group, which recently separated from its consumer drugs branch Haleon, raised its annual objectives, now expecting growth of around 1% of its EPS. adjusted in 2022, based on an expected revenue increase of 6% to 8%.
UBS analysts nevertheless evoked a limited increase and the title rose only 0.6% on the London Stock Exchange after these announcements.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
